Related Experiment Video
Updated: Apr 6, 2026
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
7.0K
Minimally Invasive Retroperitoneal Lymphadenectomy: Current Status
Thomas Kunit1, Günter Janetschek1
1Department of Urology, Paracelsus Medical University Salzburg, Müllnerhauptstr 48, Salzburg 5020, Austria.
The Urologic Clinics of North America
|July 29, 2015
Summary
Laparoscopic retroperitoneal lymphadnectomy (RLA) offers a minimally invasive alternative to open surgery for testicular cancer treatment. In experienced hands, it achieves similar oncologic outcomes with reduced patient morbidity, emphasizing the importance of careful patient selection.
Area of Science:
- Urology
- Surgical Oncology
Background:
- Retroperitoneal lymphadnectomy (RLA) is a standard surgical procedure.
- Open surgery is the traditional approach for RLA.
- Laparoscopic techniques are increasingly reported in urological procedures.
Purpose of the Study:
- To present the indications, technique, and outcomes of laparoscopic RLA.
- To evaluate laparoscopic RLA as primary treatment and post-chemotherapy management.
- To compare laparoscopic RLA with open surgery regarding invasiveness and oncologic results.
Main Methods:
- Review of laparoscopic retroperitoneal lymphadnectomy procedures.
- Analysis of patient selection criteria.
- Evaluation of surgical technique and outcomes.
- Comparison with open retroperitoneal lymphadnectomy outcomes.
Main Results:
- Laparoscopic RLA is a minimally invasive approach.
- It reduces patient morbidity compared to open surgery.
- Oncologic outcomes are comparable between laparoscopic and open RLA.
- Patient selection is critical for successful outcomes.
Conclusions:
- Laparoscopic RLA is a viable and effective treatment option.
- It offers significant advantages in terms of reduced morbidity.
- Expertise and careful patient selection are paramount for optimal results in laparoscopic RLA.
